Business

March 31, 2014

NephroGenex reports $6.3 million net loss in 2013

NephroGenex, the Research Triangle Park drug developer that raised $37 million in an initial public offering of stock last month, reported a wider net loss last year.

Related content

Comments

Editor's Choice Videos